Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis
Open Access
- 26 June 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 54 (11), 2015-2024
- https://doi.org/10.1093/rheumatology/kev201
Abstract
Objective. Digital vasculopathy (comprising RP, digital ulceration and critical digital ischaemia) is responsible for much of the pain and disability experienced by patients with SSc. However, there is a limited evidence base to guide clinicians in the management of SSc-related digital vasculopathy. Our aim was to produce recommendations that would be helpful for clinicians, especially for those managing patients outside specialist centres. Methods. The UK Scleroderma Study Group set up several working groups to develop a number of consensus best practice pathways for the management of SSc-specific complications, including digital vasculopathy. Results. This overview presents the background and best practice consensus pathways for SSc-related RP, digital ulceration and critical ischaemia. Examples of drug therapies, including doses, are suggested in order to inform prescribing practice. Conclusion. A number of treatment algorithms are provided that are intended to provide the clinician with accessible reference tools for use in daily management.Keywords
This publication has 36 references indexed in Scilit:
- Review: Evidence That Systemic Sclerosis Is a Vascular DiseaseArthritis & Rheumatism, 2013
- Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group databaseAnnals Of The Rheumatic Diseases, 2012
- The Pathogenesis of Systemic SclerosisAnnual review of pathology, 2011
- Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosisArthritis & Rheumatism, 2010
- SclerodermaThe New England Journal of Medicine, 2009
- EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)Annals Of The Rheumatic Diseases, 2009
- Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysisRheumatology, 2004
- Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosisArthritis & Rheumatism, 2001
- Raynaud's phenomenonThe Lancet, 2001
- Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosisToxicology, 2000